Table 2 Clinical significance of predictive biomarkers in chronic lymphocytic leukemia
From: Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia
Predictive biomarkers | Clinical significance |
|---|---|
Del 17p/ TP53 mutation | Predicts poor response to chemo-immunotherapy |
NOTCH1 mutation | Predicts poor response to anti-CD20 therapy |
CD49d | Inhibits cell trafficking in the setting of novel BCR target therapy |
IGHV mutation status | Gives its potential for long-term remission in the use of BCR in younger, fit patients with M-IGHV |
Complex karyotypes | Predict poor response to chemo-immunotherapy when complex karyotypes with major structural abnormalities. |
MicroRNAs | MiR-34a: associates with chemotherapy-refractory disease MiR-155: predicts therapy response |